Introduction
============

Human genetic studies have linked many variants to human diseases or nondisease phenotypes. How to handle the incidental finding of a disease variant is a topic of current discussion (Green et al. [@b24]; Klitzman et al. [@b36]). Incidental findings often occur, when genome sequencing data are screened for disease-causing variants that are recorded in databases such as Online Mendelian Inheritance in Man (OMIM) (Hamosh et al. [@b26]) or, more recently, ClinVar (Landrum et al. [@b37]) and the Genome Wide Association Studies (GWAS) catalog (Hindorff et al. [@b28]). However, the penetrance of these recorded variants spans a broad spectrum, ranging from complete penetrance for a set of monogenic mutations to the very small effect sizes of many GWAS hits. While it is widely known that most GWAS hits have only limited clinical prognostic relevance, the penetrance and prognostic value of many previously reported monogenic mutations is less clear. Recently, a significant percentage of such putative "disease mutations" were claimed to be of questionable pathogenicity (Cassa et al. [@b12]; Dorschner et al. [@b18]; Flannick et al. [@b20]; Kenna et al. [@b32]; Riggs et al. [@b57]). Accordingly, it is an important aim of current human genetic research to systematically assess the clinical significance of genetic variants (Duzkale et al. [@b19]). As one way to identify those mutations that may require reinterpretation, we use a sample of individuals with exceptional longevity to identify reported disease mutations for which the pathogenicity status should be preferentially reevaluated.

If a mutation for a dominant late-onset disease is encountered in the genome of a younger individual, a reduced penetrance is difficult to assign without longitudinal follow-up. In addition to the uncertain significance of many reported mutations for dominant diseases, the traditional assumption that heterozygous carriers for recessive disease alleles are unaffected (Nussbaum et al. [@b52]) may not hold true. For instance, Gaucher\'s disease alleles in the *GBA* gene have been found to strongly increase the risk of developing Parkinson\'s disease (Sidransky et al. [@b60]) as well as dementia with Lewy bodies (Nalls et al. [@b51]). Similarly, heterozygous carriers for autosomal recessive disease alleles for Alport syndromes have increased risk of renal failure (Temme et al. [@b64]). Therefore, different lines of evidence need to be integrated to assign a clinical significance score to each variant. For mutations previously linked to dominant diseases that negatively affect life expectancy, their observation in centenarian genomes may be viewed as evidence for unclear pathogenicity or at least incomplete penetrance. To a certain extent, reduced penetrance could result from a variety of protective genetic, epigenetic, environmental, and random factors (Cooper et al. [@b13]) or other buffering mechanisms (Bergman et al. [@b6]).

In the present study, we search the coding regions of 44 Ashkenazi Jewish (AJ) centenarians for variants that were previously reported as causal mutations for medically relevant phenotypes. To this end, we use the recently established and publicly accessible ClinVar database (Riggs et al. [@b57]) which not only provides highly structured data access but also includes community-based data curation (Landrum et al. [@b37]). We chose ClinVar because of the quality of its content. Our study is meant to be part of the community effort to further improve its quality, which is eased by its free availability. Such databases are gaining in importance, because the increased utilization of next-generation sequencing technology magnifies the challenge to interpret genetic testing results (Lyon and Wang [@b41]; Lohn et al. [@b40]; Manolio et al. [@b43]; Rehm et al. [@b56]). For example, in August 2013 the ClinVar database recorded 14,746 variants classified as pathogenic and 1672 as probably pathogenic. We focus on the description of those variants that have been previously reported as Mendelian disease mutations that would increase the risk of mortality, such as degenerative diseases, neoplasm, and cardiac diseases. The observation of previously reported disease variants in centenarian genomes may aid clinical geneticists who are confronted with the challenge to evaluate their pathogenicity.

Materials and Methods
=====================

Study population
----------------

DNA samples of 44 AJ centenarians were collected as part of a longevity study at the Albert Einstein College of Medicine that was described elsewhere (Barzilai et al. [@b4]). The sample includes eight male (95--103 years old) and 36 female (95--106 years old) subjects. The mean and median age of the subjects was 99.6 and 100 years (standard deviation *σ* = 3.1). Informed written consent was obtained in accordance with the policy of the Committee on Clinical Investigations of the Albert Einstein College of Medicine. Genomic DNA extracted from blood cells using standard procedure was sent for sequencing. Mini-mental status examinations (MMSE) (Folstein et al. [@b21]) and selected health status information such as hearing, vision, and whether a subject had a history of cancer or myocardial infarction (MI) are available for the majority of the centenarians. The level of education was not available. Given that median MMSE scores are found to be a function of age and level of education (Crum et al. [@b15]; Bravo and Hebert [@b9]) and can be as low as 20 for people 85 years and older with \<4 years of education (Crum et al. [@b15]), we use the reference score of ≥24 (one standard deviation of the mean MMSE score for people 85 and older; Bravo and Hebert [@b9]) to exclude the presence of dementia in our sample. To our knowledge, no reference MMSE scores specifically for centenarians are available.

Genome sequencing and variant calling
-------------------------------------

Whole genome sequencing was performed on Illumina HiSeq 2000 platform (Illumina, San Diego, CA). Paired-end 2 × 100 reads were aligned to the GRCh37 human reference using the Burrows-Wheeler Aligner (BWA) (Li and Durbin [@b39]) and processed using the best-practices pipeline that includes marking of duplicate reads by the use of Picard tools (<http://picard.sourceforge.net>), and realignment around DNA insertions and deletions (indels) and base recalibration via Genome Analysis Toolkit (GATK) Lite ver. 2.3-9 (McKenna et al. [@b45]). Single-nucleotide variants (SNVs) were jointly called on the 44 unrelated AJ centenarians together with HapMap trio NA12877, NA12878, and NA12882 using the UnifiedGenotyper module of GATK Lite. The HapMap trio was sequenced at Illumina and released as part of the PlatinumGenomes project (<http://www.illumina.com/platinumgenomes>). We used variant quality score recalibration and Mendelian inconsistencies on the HapMap trio to determine the optimal variant quality score (VQSLOD) cutoff.

Joint calling for transcribed gene regions of 44 AJ centenarians identified a total of 6.3 million genetic variants. A total of 87,899 coding SNVs were found (100% call rate) in coding regions defined by the longest transcript according to the UCSC hg19 database (Meyer et al. [@b46]). For variants with a VQSLOD score \>2, the concordance rate for SNVs between Illumina 2.5M chip and GATK variant calls was above 99.7% for all subjects. Due to the comparatively lower performance of the UnifiedGenotyper in calling short insertions and deletions, in the present study we decided not to analyze insertion/deletion variants.

Database annotation of variants
-------------------------------

Using custom scripts and the SNP & Variation Suite software (Version 7.7.8; Golden Helix, Inc., Bozeman, MT, <http://www.goldenhelix.com>), we annotated coding and splice variants based on the knownGene and the refGene tracks in the UCSC hg19 database (Meyer et al. [@b46]). To find variants of potential clinical relevance, variants were evaluated for their possible pathogenicity based on the August 2013 version of the ClinVar database (<http://www.ncbi.nlm.nih.gov/clinvar/>) (Riggs et al. [@b57]). This database provides free highly structured public access to clinically relevant sequence variants and it also provides evidence-based interpretation of clinical significance for each variant (Landrum et al. [@b37]). All ClinVar accession numbers for the identified variants are linked to the respective NCBI (The National Center for Biotechnology Information) database for reference sequences (RefSeq) as well as OMIM accession numbers. Population allele frequencies of variants were retrieved from the NHLBI Exome Sequencing Project (ESP) database (Exome Variant Server, NHLBI GO ESP, Seattle, WA) (<http://evs.gs.washington.edu/EVS>). To our knowledge, a similar large-scale population allele frequency data specific for the AJ population are currently not available.

Quality control filtering of putative disease variants
------------------------------------------------------

A total of 225 autosomal and seven X-chromosomal coding SNVs were found to be annotated as "pathogenic" or "likely pathogenic" in the ClinVar database. Eighteen of these variants had a VQSLOD score \<4, most often due to poor mapping quality indicating genomic segmental duplications. However, genomic regions that are difficult to map are also known to produce false-negative variant calls (Lee and Schatz [@b38]). Therefore, we performed manual evaluation of the 18 variants. These include two mutations in the gene *GBA* that are known to cause Gaucher disease as well as being associated with late-onset Parkinson\'s disease (most frequently referred to in the literature as L444P \[uc001fjh.2:c.T1449C:p.L483P\] and N370S \[uc001fjh.2:c.A1227G:p.N409S\]). Both mutations are known to be relatively frequent in the AJ population (Scott et al. [@b59]). Using BLAT (Kent [@b33]), N409S (rs76763715) was uniquely mapped to chromosome 1:155205634 and L483P (rs421016) was uniquely mapped to chr1:155205043. Thus, both variants are likely to be true SNVs in our sample and were therefore retained. The remaining 16 variants with low VQSLOD scores were removed.

Results
=======

In the coding regions of 44 centenarian genomes, we found 210 autosomal and six X-chromosomal SNVs that passed quality control. Among these, 207 variants were classified as pathogenic and nine as likely pathogenic based on the ClinVar database. Excluding the two *APOE* risk variants, 86 of these SNVs were found to be common defined as minor allele frequency (MAF) of 5% or higher in either the European or African American populations in the ESP database ([Table S1](#SD1){ref-type="supplementary-material"}). Due to their high allele frequency in the general population, these 86 variants are considered unlikely to be strongly pathogenic with high penetrance and therefore not further discussed. According to the OMIM database, of the remaining 130 variants (Tables [5](#tbl5){ref-type="table"} and [S2](#SD1){ref-type="supplementary-material"}), 39 were reported to cause autosomal dominant diseases, 72 to cause autosomal recessive diseases, 6 were associated with X-chromosomal inheritance, and 13 with other modes of inheritance such as digenic, imprinting, complex, or unclear mode of inheritance.

###### 

Putative disease variants reported to cause degenerative diseases

  CHR   POS         ID            REF   ALT   AC        Gene       Effect                         CLNDBN                                                                                                 CLNACC                       OMIM
  ----- ----------- ------------- ----- ----- --------- ---------- ------------------------------ ------------------------------------------------------------------------------------------------------ ---------------------------- --------
  1     155205043   rs421016      A     G     43/1/0    *GBA*      uc001fjh.2:c.T1449C:p.L483P    Gaucher\'s disease; late-onset Parkinson\'s disease; susceptibility to dementia with Lewy body         RCV000004511; RCV000004512   606463
  1     155205634   rs76763715    T     C     43/1/0    *GBA*      uc001fjh.2:c.A1227G:p.N409S    Gaucher\'s disease; late-onset Parkinson\'s disease; susceptibility to dementia with Lewy body         RCV000004515; RCV000004516   606463
  1     156146640   rs41265017    G     A     34/10/0   *SEMA4A*   uc001fnm.2:c.G2139A:p.R713Q    Retinitis pigmentosa 35                                                                                RCV000003528                 607292
  2     38298394    rs79204362    C     T     41/3/0    *CYP1B1*   uc002rqo.2:c.G1104Ap.R368H     Glaucoma early-onset digenic                                                                           RCV000008178                 601771
  5     110441839   rs35703638    G     A     43/1/0    *WDR36*    uc003kpd.2:c.G1346A:p.A449T    Glaucoma 1, open angle                                                                                 RCV000001649                 609669
  5     110454719   rs34595252    A     G     43/1/0    *WDR36*    uc003kpd.2:c.A1974G:p.D658G    Glaucoma 1, open angle                                                                                 RCV000001647                 609669
  8     55537560    rs77775126    C     T     43/1/0    *RP1*      uc003xsd.1 :c.C1119T:p.T373l   Retinitis pigmentosa 1                                                                                 RCV000006334                 603937
  10    13178766    rs75654767    G     A     43/1/0    *OPTN*     uc001ilx1:c.G1635A:p.R545Q     Glaucoma 1, open angle                                                                                 RCV000007515                 602432
  12    57431402    rs33962952    C     T     32/10/2   *MY01A*    uc001smw.3:c.G1986Ap.G662E     Deafness, autosomal dominant 48                                                                        RCV000008627                 601478
  12    57437119    rs55679042    C     T     43/1/0    *MY01A*    uc001 smw.3:c.G917A:p.V306M    Deafness, autosomal dominant 48                                                                        RCV000008625                 601478
  19    45411941    rs429358      T     C     39/4/1    *APOE*     uc002pab.2:c.T389C:p.C130R     Hyperlipoproteinemia, type 3, autosomal dominant; Alzheimer\'s disease associated with APOE4 variant   RCV000019438; RCV000019448   107741
  19    45412079    rs7412        C     T     33/11/0   *APOE*     uc002pab.2:c.C527T:p.R176C     Familial type 3 hyperlipoproteinemia, associated with APOE2                                            RCV000019428                 107741
  20    25060096    rs74315433    C     T     43/1/0    *VSX1*     uc002wuf.2:c.G480Ap.G160D      Keratoconus 1                                                                                          RCV000024251                 605020
  X     56591879    rs369947678   c     T     43/1/0    *UBQLN2*   uc004dus.2:c.C1574T:p.P525S    Amyotrophic lateral sclerosis 15 with or without frontotemporal dementia                               RCV000022846                 300264

CHR, chromosome; POS, position on chromosome based on GRCh37; ID, dbSNP ID; REF, reference sequence; ALT, alternative sequence; AC, counts of subjects with homozygous reference alleles/heterozygous/homozygous nonreference alleles; Effect, position of nucleotide change on UCSC transcript and amino acid change; CLNDBN and CLNACC, selected disease condition and accession ID from ClinVar; OMIM, OMIM accession numbers for the genes.

###### 

Putative disease variants reported to cause neoplastic diseases

  CHR   POS         ID            REF   ALT   AC       Gene       Effect                         CLNDBN                                 CLNACC         OMIM
  ----- ----------- ------------- ----- ----- -------- ---------- ------------------------------ -------------------------------------- -------------- --------
  1     17354297    rs33927012    A     G     43/1/0   *SDHB*     uc001 bae.2:c.T488C:p.S163P    Cowden-like syndrome                   RCV000013633   185470
  1     182555149   rs74315364    C     A     43/1/0   *RNASEL*   uc001gpj.1:c.G794T:p.E265\*    Prostate cancer, hereditary            RCV000013878   180435
  5     112175240   rs1801166     G     C     43/1/0   *APC*      uc003kpy.3:c.G3950C:p.E1317Q   Adenomatous polyposis coli             RCV000000872   611731
  8     16012594    rs41341748    G     A     43/1/0   *MSR1*     uc003wwz.2:c.C878T:p.R293\*    Malignant tumor of prostate            RCV000015431   153622
  10    43613908    rs77724903    A     T     42/2/0   *RET*      uc001jal.2:c.A2373T:p.Y791 F   Familial medullary thyroid carcinoma   RCV000014962   164761
  11    67258382    rs104894190   G     A     41/3/0   *MP*       uc001olv.2:c.G912A:p.R304Q     Pituitary-dependent hypercortisolism   RCV000005171   605555
  17    12899902    rs5030739     C     T     38/6/0   *ELAC2*    uc002gnz.3:c.G1622A:p.A541 T   Prostate cancer, hereditary            RCV000005359   605367
  17    41226488    rs1800744     C     A     42/2/0   *BRCA1*    uc002ict.2:c.G4599T:p.S1533I   Familial cancer of breast              RCV000048588   113705
  19    1223125     rs59912467    C     G     43/1/0   *STK11*    uc002lrl.1:c.C1063G:p.F355L    Peutz--Jeghers syndrome                RCV000007887   602216

CHR, chromosome; POS, position on chromosome based on GRCh37; ID, dbSNP ID; REF, reference sequence; ALT, alternative sequence; AC, counts of subjects with homozygous reference alleles/heterozygous/homozygous nonreference alleles; Effect, position of nucleotide change on UCSC transcript and amino acid change; CLNDBN and CLNACC, selected disease condition and accession ID from ClinVar; OMIM, OMIM accession numbers for the genes.

###### 

Putative disease variants reported to cause autosomal dominant cardiac diseases

  CHR   POS         ID            REF   ALT   AC       Gene        Effect                          CLNDBN                                    CLNACC         OMIM
  ----- ----------- ------------- ----- ----- -------- ----------- ------------------------------- ----------------------------------------- -------------- --------
  1     236918491   rs193922635   C     T     43/1/0   *ACTN2*     uc001hyf.2:c.C2148T:p.T716M     Cardiomyopathy                            RCV000029298   102573
  3     14180731    rs113449357   C     T     43/1/0   *TMEM43*    uc003byk.2:c.C935T:p.R312W      Cardiomyopathy                            RCV000030555   612048
  4     114294537   rs45454496    G     A     42/2/0   *ANK2*      uc003ibe.3:c.G11792A:p.E3931K   Cardiac arrhythmia, ankyrin B-related     RCV000019677   106410
  12    2659186     rs121912775   G     A     43/1/0   *CACNA1C*   uc001qkl.2:c.G1469A:p.G490R     Brugada syndrome 3                        RCV000019201   114205
  12    22017410    rs61688134    C     T     42/2/0   *ABCC9*     uc001 rfh.2:c.G2201 A:p.V734l   Myocardial infarction 1                   RCV000029274   601439
  12    111356964   rs104894363   C     T     43/1/0   *MYL2*      uc001try.3:c.G38Ap.A13T         Familial hypertrophic cardiomyopathy 10   RCV000015108   160781
  20    42744802    rs140740776   C     T     42/2/0   *JPH2*      uc002xli.1:c.G1514A:p.G505S     Familial hypertrophic cardiomyopathy 17   RCV000023411   605267
  21    35742938    rs74315447    T     C     43/1/0   *KCNE2*     uc002ytt.1 :c.T162C:p.M54T      Long QT syndrome 6                        RCV000006425   603796

CHR, chromosome; POS, position on chromosome based on GRCh37; ID, dbSNP ID; REF, reference sequence; ALT, alternative sequence; AC, counts of subjects with homozygous reference alleles/heterozygous/homozygous nonreference alleles; Effect, position of nucleotide change on UCSC transcript and amino acid change; CLNDBN and CLNACC, selected disease condition and accession ID from ClinVar; OMIM, OMIM accession numbers for the genes.

###### 

Putative disease variants reported to cause other autosomal dominant diseases

  CHR   POS         ID            REF   ALT   AC       Gene         Effect                          CLNDBN                                                    CLNACC         OMIM
  ----- ----------- ------------- ----- ----- -------- ------------ ------------------------------- --------------------------------------------------------- -------------- --------
  1     152285861   rs61816761    G     A     42/2/0   *FLG*        uc001 ezu.1:c.C1502T:p.R501\*   Ichthyosis vulgaris                                       RCV000017712   135940
  2     167141109   rs41268673    G     T     36/7/1   *SCN9A*      uc010fpl.2:c.C1829A:p.P610T     Primary erythromelalgia                                   RCV000020511   603415
  2     219755011   rs121908120   T     A     41/3/0   *WNT10A*     uc002yjd.1:c.T683Ap.F228l       Odontoonychodermal dysplasia                              RCV000004717   606268
  5     172662014   rs28936670    G     A     43/1/0   *NKX2-5*     uc003mcm.1:c.C74T:p.R25C        Tetralogy of Fallot                                       RCV000009572   600584
  5     172662026   rs104893904   C     G     43/1/0   *NKX2-5*     uc003mcm.1:c.G62C:p.E21Q        Tetralogy of Fallot                                       RCV000009574   600584
  6     32052313    rs121912575   C     T     42/2/0   *TNXB*       uc003nzl.2:c.G3323Ap.V1108M     Ehlers--Danlos syndrome type 3                            RCV000009083   600985
  8     11405576    rs55758736    G     A     42/2/0   *BLK*        uc003wty.2:c.G212Ap.A71T        Maturity-onset diabetes of the young type 11              RCV000013112   191305
  8     18080001    rs4987076     G     A     39/5/0   *NAT1*       uc003wys.2:c.G632A:p.V211l      NAT1\*7 ALLELE                                            RCV000019386   108345
  8     55372085    NA            T     A     42/2/0   *SOX17*      uc003xsb.3:c.T776Ap.Y259N       Vesicoureteral reflux 3                                   RCV000001140   610928
  8     106431420   rs121908601   A     G     42/2/0   *ZFPM2*      uc003ymd.2:c.A90G:p.E30G        Tetralogy of Fallot                                       RCV000006502   603693
  12    6442643     rs4149584     C     T     41/3/0   *TNFRSF1A*   uc001qnu.2:c.G363A:p.R121Q      TNF receptor-associated periodic fever syndrome (TRAPS)   RCV000013134   191190
  13    32351535    rs121918303   A     C     38/6/0   *RXFP2*      uc001 utt.2:c.A665C:p.T222P     Cryptorchidism, unilateral or bilateral                   RCV000004376   606655
  14    54418579    NA            T     C     43/1/0   *BMP4*       uc010aoh.2:c.A363G:p.H121R      Microphthalmia syndromic 6                                RCV000022458   112262
  15    74704267    rs56001514    G     A     43/1/0   *SEMA7A*     uc002axv.2:c.C1382T:p.R461C     Blood group John Milton Hagen system                      RCV000029235   607961
  16    1129586     rs121917877   C     T     42/2/0   *SSTR5*      uc002ckq.2:c.C719T:p.R240W      Resistance to somatostatin analog                         RCV000013734   182455
  17    72745313    rs35910969    C     G     43/1/0   *SLC9A3R1*   uc002jlo.2:c.C329G:p.L110V      Nephrolithiasis/osteoporosis, hypophosphatemic 2          RCV000005588   604990
  18    58039060    rs121913563   C     T     43/1/0   *MC4R*       uc002lie.1:c.G524A:p.A175T      Obesity                                                   RCV000015406   155541
  19    11240278    rs137853964   G     A     43/1/0   *LDLR*       uc002mqk.3:c.G2480A:p.V827l     Familial hypercholesterolemia                             RCV000030135   606945

CHR, chromosome; POS, position on chromosome based on GRCh37; ID, dbSNP ID; REF, reference sequence; ALT, alternative sequence; AC, counts of subjects with homozygous reference alleles/heterozygous/homozygous nonreference alleles; Effect, position of nucleotide change on UCSC transcript and amino acid change; CLNDBN and CLNACC, selected disease condition and accession ID from ClinVar; OMIM, OMIM accession numbers for the genes.

###### 

Putative disease mutations reported to cause X-chromosomal diseases

  CHR   POS         ID           REF   ALT   ALT_AC   ALT_AC (male)   Gene         Effect                         CLNDBN                                 CLNACC         OMIM
  ----- ----------- ------------ ----- ----- -------- --------------- ------------ ------------------------------ -------------------------------------- -------------- --------
  X     31496398    rs1800279    T     C     4        1               *DMD*        uc004dda.1:c.A8763G:p.H2921R   Becker muscular dystrophy              RCV000012020   300377
  X     31496426    rs1800278    T     C     1        1               *DMD*        uc004dda.1:c.A8735G:p.N2912D   Duchenne muscular dystrophy            RCV000012019   300377
  X     31496431    rs41305353   T     A     1        1               *DMD*        uc004dda.1:c.A8730T:p.E2910V   Duchenne muscular dystrophy            RCV000012018   300377
  X     84563194    rs75398746   C     T     2        0               *POF1B*      uc004eer.2:c.G987A:p.R329Q     Premature ovarian failure 2b           RCV000011541   300603
  X     105278361   rs1804495    C     A     11       1               *SERPINA7*   uc004eme.1:c.G910T:p.L304F     Thyroxine-binding globulin variant p   RCV000010442   314200

CHR, chromosome based on GRCh37; POS, position on chromosome; ID, dbSNP ID; REF, reference sequence; ALT, alternative sequence; ALT_AC, nonreference allele counts; Effect, position of nucleotide change on UCSC transcript and amino acid change; CLNDBN and CLNACC, selected disease condition and accession ID from ClinVar; OMIM, OMIM accession numbers for the genes.

Variants reported as causal for degenerative diseases of advanced age
---------------------------------------------------------------------

Variants associated with age-related degenerative diseases were found in the genes *APOE*, *GBA*, *UBQLN2*, *SEMA4A*, *RP1*, *MYO1A*, *CYP1B1*, *OPTN*, *VSX1*, and *WDR36* (Table [1](#tbl1){ref-type="table"}).

Given the important role of *APOE* variants in late-onset Alzheimer\'s disease, we first looked at the *APOE ε*4 allele as defined by the ancestral alleles rs429358-C and rs7412-C (130Arg and 176Arg) and *APOE ε*2 allele as defined by rs429358-T and rs7412-T (130Cys and 176Cys). In our centenarian sample, the allele frequencies for *APOE ε*4, *ε*3, and *ε*2 were 6.8%, 80.7%, and 12.5%, respectively. One of the two *ε*2/*ε*4 and one of the two *ε*3/*ε*4 heterozygous carriers were found to have advanced dementia of unknown etiology and the other two subjects were cognitively intact. Notably, the centenarian homozygous for the *ε*4 allele had an MMSE score of 25 at age 97. Neither this centenarian nor any other subject in our study carried the protective variant A673T in the *APP* gene (Jonsson et al. [@b30]). We also observed one carrier for each of the known *GBA* mutations L483P (also known as L444P) (rs421016) and N409S (N370S) (rs76763715), which is in line with the reported frequency of 3% for either mutation in AJ controls (Sidransky et al. [@b60]).

On the X chromosome we identified a female centenarian with a previously described mutation in *UBQLN2* P525S (Deng et al. [@b17]), which was found to cause an X-linked dominant type of familial amyotrophic lateral sclerosis (ALS) and ALS/dementia with an estimated penetrance of approximately 90% (Table [1](#tbl1){ref-type="table"}). This subject had normal MMSE (score = 28) at age 102 without any neurological symptoms.

Furthermore, disease alleles were observed for other autosomal dominantly inherited degenerative diseases of sensory function, including retinitis pigmentosa (*SEMA4A*, *RP1*), deafness (*MYO1A*), glaucoma (*CYP1B1*, *OPTN*, *WDR36*), and keratoconus (*VSX1*). Of note, none of the 10 centenarians carrying the *SEMA4A* R713Q had vision impairment but the single subject carrying the *RP1* T373I was blind. No hearing impairment was noticed in one of two subjects homozygous and four of ten heterozygous carriers of the *MYO1A* G662E variant that was linked to an autosomal dominant form of deafness.

Variants for neoplastic diseases
--------------------------------

We found variants in the five genes *APC*, *BRCA1*, *RET*, *RNASEL*, and *STK11* that were linked to autosomal dominant forms of cancer or neoplasm as well as four complex risk variants in *ELAC2*, *MSR1*, *AIP*, and *SDHB* (Table [2](#tbl2){ref-type="table"}). The clinical relevance of these variants has been discussed in the literature and their presence in the genomes of centenarians indicates that these variants are compatible with exceptional longevity.

The tumor suppressor gene *STK11* variant F355L (rs59912467) linked to Peutz--Jeghers syndrome was seen in one centenarian. It was reported to affect both the AMPK pathway and cell polarity, thus contributing to the development of malignancies (Forcet et al. [@b22]). Notably, the same subject carried two additional variants linked to thyroid carcinoma (*RET* Y791F, rs77724903) and Cowden-like syndrome (*SDHB* S163P, rs33927012), but was free of any type of neoplasia at age 97. The Y791F variant in the *RET* protooncogene was further present in another centenarian with a history of cancer of unknown origin. This variant was first described in two German families with familial medullary thyroid carcinoma (Berndt et al. [@b7]). Six centenarians carried the A541T variant in the gene *ELAC2* (rs5030739) that was reported to be associated with prostate cancer (Rebbeck et al. [@b55]; Tavtigian et al. [@b62]; Camp and Tavtigian [@b10]). One of the two male carriers for A541T had no cancer at age 103 years and the other had an unknown type of cancer.

Variants for autosomal dominant forms of cardiac disease
--------------------------------------------------------

We found variants in *ABCC9*, *ACTN2*, *ANK2*, *CACNA1C*, *JPH2*, *KCNE2*, *MYL2*, and *TMEM43* that were linked to autosomal dominant phenotypes affecting cardiac function (Table [3](#tbl3){ref-type="table"}).

Three of the variants in these genes are annotated as causes of cardiac arrhythmia with increased risk of sudden cardiac death. Two centenarians were heterozygous for the E3931K variant in *ANK2* (rs45454496) variant, also known as E1813K, which was reported as a loss-of-function mutation in the ankyrin-B regulatory domain (Mohler et al. [@b49], [@b50]). One centenarian carried the G490R variant in *CACNA1C* (rs121912775), a loss-of-function change that was linked to Brugada syndrome 3 (Antzelevitch et al. [@b3]). Another carried the M54T (rs74315447) in *KCNE2*, which was reported to alter the transmembrane domain of MiRP1 that reduces potassium currents leading to long QT syndrome and ventricular fibrillation (Abbott et al. [@b1]; Splawski et al. [@b61]).

Five variants linked to cardiomyopathy were found in our centenarian sample. The *MYL2* A13T (rs104894363) variant located in the regulatory light chain of myosin was reported to be causal for a subtype of familial hypertrophic cardiomyopathy with onset of clinical symptoms around middle age (Poetter et al. [@b54]; Andersen et al. [@b2]). The gene *ABCC9* encodes the regulatory *SUR2A* subunit of the cardiac ATP-sensitive potassium (K~ATP~) channel. Two centenarians carried the *ABCC9* V734I variant (rs61688134), which was reported to increase the risk of MI by 6.40-fold. (Minoretti et al. [@b48]). The G505S (rs140740776) variant in *JPH2* was reported to be associated with hypertrophic cardiomyopathy in a relatively small sample of Japanese patients (Matsushita et al. [@b44]). One centenarian carried the *TMEM43* R312W variant linked to autosomal dominant arrhythmogenic right ventricular cardiomyopathy/dysplasia (Haywood et al. [@b27]). Interestingly, one centenarian was found to be heterozygous for both *JPH2* G505S and *ABCC9* V734I and another was heterozygous for both *JPH2* G505S and *ANK2* E3931K.

Variants for other autosomal dominant and X-chromosomal diseases
----------------------------------------------------------------

We found 18 rare ClinVar variants for other autosomal dominant diseases (Table [4](#tbl4){ref-type="table"}) and six mutations for X-chromosomal diseases (Table [5](#tbl5){ref-type="table"}). These include variants that increase the risk of metabolic disorders, including hypercholesterolemia (*LDLR*, V827I, rs137853964), maturity-onset diabetes of the young (MODY) (*BLK*, A71T, rs55758736), and obesity (*MC4R*, A175T, rs121913563). One male and one female centenarian carried the V1108M variant in *TNXB* (rs121912575) linked to the dominant form of Ehlers--Danlos syndrome type 3 (Zweers et al. [@b66]). The remaining autosomal mutations are annotated to cause a wide range of dominantly inherited phenotypes including metabolic, genitourinary, and skin conditions as well as pediatric conditions, including developmental syndromes, for example, the tetralogy of Fallot, a severe malformation that would reduce life span. Three centenarians presented a variant in *TNFRSF1A* (R121Q, rs4149584) in the heterozygous state that was linked to TNF-receptor associated periodic fever. This was the only variant for dominantly inherited immune disease in this dataset.

Aside from the above mentioned mutation in *UBQLN2*, the observed X-chromosomal variants include three variants in the *DMD* gene that have been discussed as cause of Duchenne and Becker muscular dystrophy. One frequent missense variant rs1800279 (H2921R) in the *DMD* gene was observed in one male centenarian and another male centenarian carried both rare variants rs1800278 (N2912D) and rs41305353 (E2910V). The carriers did not have any documented muscle diseases.

Variants for recessive diseases and complex diseases
----------------------------------------------------

Among the 72 variants for recessive traits, we found three variants that were observed in the homozygous state in at least one centenarian (Table S2). These are variants in *ADA*, *ALG6*, and *HPS5*. The *ALG6* variant Y131H (rs35383149) has been annotated to cause congenital disorder of glycosylation, type Ic, a childhood onset metabolic disorder accompanied by severe neurological symptoms (Miller et al. [@b47]). We found no literature evidence supporting the pathogenicity of the *ADA* variant D8N (rs73598374) or the *HPS5* variant T1098I (rs61884288).

Three subjects were heterozygous carriers for Factor V Leiden (*F5*, Q534R, rs6025) (Bertina et al. [@b8]). Heterozygous carriers have elevated risks of deep venous thrombosis, pulmonary embolism (Juul et al. [@b31]), and stroke (Casas et al. [@b11]). Note that the GRCh37 genome assembly presents the risk allele as the reference allele and no individuals homozygous for the reference allele were seen in our sample. One carrier had a history of MI and another had a history of both MI and stroke, but the third carrier had no known thrombotic diseases by the age of 106 years.

Finally, we also identified homozygous individuals for putative recessive disease alleles with relevance for longevity regardless of their population allele frequency. Of note, we found three missense variants in the *ACADS* gene R107C (rs61732144), R171W (rs1800556), and G209S (rs1799958) (Tables S1 and S2) that were initially reported (Corydon et al. [@b14]; Pedersen et al. [@b53]) in 10 patients with ethylmalonic aciduria and short-chain acyl-CoA dehydrogenase (SCAD) deficiency, a mitochondrial fatty acid oxidation disorder causing neuromuscular phenotypes with hypotonia and developmental delay as the prominent features of the disease. Homozygosity for R107C as well as compound heterozygosity for R107C and G209S have been described as disease causing in AJ patients with SCAD with reduced penetrance (Tein et al. [@b63]) depending on other genetic modifiers or environmental stressors. Variants R171W and G209S have both high allele frequencies (5.5% and 23.5%, respectively) in the general population (U.S. and the Netherlands) and they are considered to confer susceptibility for clinical disease (van Maldegem et al. [@b42]). We found five AJ centenarians who are homozygous for the variant G209S (MAF = 36.4%) and they do not carry any other missense variants in the *ACADS* gene. The carrier frequency for the R107C variant in our centenarians (3/44) is identical to the reported carrier frequency in AJ population (Tein et al. [@b63]).

Discussion
==========

In this study we observed many previously reported Mendelian mutations that are sufficiently benign to allow the individual carriers to achieve exceptional longevity. The presence of these specific variants in the genomes of centenarians can be helpful for clinical geneticists who are challenged with the evaluation of their putative pathogenicity as incidental findings. More generally, our findings support the notion that for many putative disease variants it is not straightforward to decide whether they should be regarded and acted upon as incidental findings, when they are observed in healthy individuals (Kingsmore [@b35]). Several genes harboring putatively pathogenic variants in our centenarians are on the list of 57 genes with reportable findings according to the ACMG recommendations (Green et al. [@b25]). These genes comprise 4 of the 24 genes for cancer (*BRCA1*, *APC*, *RET*, *STK11*), 1 of the 20 cardiac disease genes (*TMEM43*), 1 of the remaining 13 genes (*LDLR*). This demonstrates the challenge to identify actionable mutations even in well-established disease genes. The variants found in four of the cancer genes *APC*, *BRCA1*, *RET*, and *SDHB* in our AJ centenarian sample had also been labeled as "almost certainly benign" in another sequencing study (ClinSeq) of 572 middle aged participants (17% of which are of AJ ancestry) (Johnston et al. [@b29]). Surprisingly, we also observed many rare variants linked to dominantly inherited forms of diseases that would clearly affect life expectancy. These disease traits include cardiac diseases such as cardiomyopathy and arrhythmia that increase the risk of sudden cardiac death as well as metabolic diseases such as diabetes, hypercholesterolemia, and obesity. One explanation for the presence of disease alleles in centenarians might be that these variants have incomplete penetrance as a result of complex interplay between modifying genetic and environmental factors (Bergman et al. [@b6]; Cooper et al. [@b13]). However, for some variants the published evidence may be viewed as too weak to uphold their classification as pathogenic. For example, the three missense variants in the *DMD* gene were all found in at least one male centenarian. Given the markedly reduced life expectancy of patients affected by Duchenne muscular dystrophy (Kieny et al. [@b34]), it is unlikely that these variants are pathogenic. In other cases, the resulting phenotypes of mutations could have little impact on longevity, which may primarily apply to diseases such as deafness, glaucoma, retinitis pigmentosa, premature ovarian failure, or ichthyosis. In other instances the possible influence on life expectancy is not clear, such as the variant V1108M in the *TNXB* gene, which was reported to cause Ehlers--Danlos syndrome type 3 (Zweers et al. [@b66]) and shown to affect the protein function (Zhuang et al. [@b65]).

We note that many presumable disease mutations are present in centenarians with fairly high frequency. We did not discuss these variants in detail because they are common in the ESP data. With the exception of the APOE *ε*4 allele, these common variants are from the beginning more likely to constitute polymorphisms than any clinically significant mutations. Despite its high population frequency, the APOE *ε*4 allele was suggested to follow semi-dominant inheritance (Genin et al. [@b23]). *APOE* is also the only reported gene reaching GWAS significance threshold for longevity (Beekman et al. [@b5]). In our centenarian sample, the APOE *ε*4 allele frequency is very similar to the previously reported allele frequencies in 325 French Caucasian centenarians (Schachter et al. [@b58]), namely 5.2% for APOE *ε*4 and 12.8% for APOE *ε*2. In the ESP dataset, the respective allele frequencies for *ε*4 and *ε*2 are 11.7% and 5.6% in European Americans and 18.9% and 8.7% in African Americans. This is congruent with the previous finding that *ε*4 was associated with reduced and *ε*2 with increased life span (Deelen et al. [@b16]). However, earlier studies did not observe any homozygote centenarians for APOE *ε*4. As would be expected, the nonaffected APOE *ε*4 homozygote had rare coding variants in APOE modifier candidate genes, but testing their significance needs to be left to subsequent studies. The future identification of such protective genetic factors in centenarians may increase the clinical utility of the APOE *ε*4 allele. Due to the relatively small sample size and lack of a control data set from a matched population, we cannot search for novel variants with impact on longevity here.

In future, personalized genomic sequencing is likely to generate many incidental findings. Rigorous investigations for cosegregation in family members, large ancestry-matched population screening, and functional studies will be required to identify those variants that are sufficiently penetrant to be considered clinically relevant. Genetic counseling provided by trained clinicians will be necessary to communicate the potential impact of genetic variants to avoid unnecessary and far reaching burden. This is especially true in considering genetic screening in the young, where the demarcation of putatively actionable mutations needs to be approached with considerable caution, allowing appropriate balance to be conveyed in risk/benefit discussions with parents. Our study provides a list of variants that are currently flagged as pathogenic, but are compatible with exceptional longevity. Thereby, our study contributes to the genetic community\'s efforts to refine the set of variants with strong clinical significance and mark previously reported disease mutations with unclear clinical significance.
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**Table S1.** Putative disease alleles found in AJ Centenarians that have minor allele frequency ≥5% in either Europeans or African Americans from the Exome Sequencing Project (ESP).
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**Table S2.** Putative disease variants reported to cause autosomal recessive diseases and diseases with other mode of inheritance.
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